You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Real World Evidence

BEXSERO has a foundation of evidence data, which you may consider when vaccinating against meningococcal serogroup B disease (MenB). This data can help you better understand how BEXSERO can help protect patients in the real world - and not just in the setting of a clinical trial.

BEXSERO has shown an impact following a mass vaccination campaign against MenB disease in a region of Canada 1

In the Saguenay-Lac-Saint-Jean region of Quebec, Canada, 83% of population 2 months to 20 years (~59,500 individuals) was immunized at least with one dose with Bexsero in 2014 in response to a MenB outbreak. 1

In the four years following the vaccination campaign, serogroup B incidence fell by 96% from 11.4 to 0.4/100,000 between the periods of 2006-14 to 2014-18. 1 The four years following the vaccination compaign, serogroup B incidence fell by 96% from 11.4/100.000 in 2006-14 to 0.4/100.000 in 2014-18 (p<0.0001).

MenB cases per 100,000

Reduction in MenB incidence during the BEXSERO vaccination program in Saguenay-Lac-St-Jean (Quebec, Canada). From 2014-2018 an estimated 83% of 59,000 residents aged 2 months to 20 years of age received at least 1 dose of Bexsero. 1


  1. Deceuninck G et al. Vaccine. 2019. 37(31):4243–4245.

Prescription Only Medicine.
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.